Completed PHASE4 INTERVENTIONAL 3-arm NCT00902512

Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations

Relative Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations In Healthy Volunteers Under Fasting Conditions.

Sponsor: Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.

Conditions Healthy Males

Interventions Blood samples for the analysis of sildenafil in plasma Treatment A Treatment B Treatment C

Updated 6 times since 2017 Last updated: Jan 28, 2021 Started: Apr 30, 2009 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Healthy Males, this trial is completed. The trial is conducted by Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V. and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Mar 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Mar 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Col. Arenal Tepepan, Mexico